News | Prostate Cancer | December 31, 2015

Leading HIFU Expert Begins U.S.-Based Program with Treatment of First Prostate Cancer Patients

Patients with prostate cancer are now being treated with minimally invasive, high intensity focused ultrasound (HIFU) therapy, following the October 2015 U.S. Food and Drug Administration (FDA) regulatory authorization for prostate tissue ablation with the Sonablate HIFU device. The leading U.S. HIFU expert, Vituro Health Medical Director Stephen Scionti, M.D., has begun U.S.-based HIFU procedures.

Scionti is the first partner physician of Vituro Health, a comprehensive prostate care provider that empowers men during all stages of life. Prior to the FDA clearance, Scionti had been involved in the treatment of approximately 1,000 patients over the last decade at the International HIFU Prostate Cancer Centers in the Caribbean and Mexico and as lead proctor for the FDA trials in the United States.

“Ten years ago, I saw HIFU as an incredible opportunity to improve the care of prostate cancer patients because the modalities we were using then had such significant limitations with significant side effects,” Scionti said. “I became an early adopter of HIFU because of the promise of an outpatient, non-invasive procedure where we could customize treatment to the patient through proper understanding of where the tumor was in their prostate.”

Scionti says HIFU offers an opportunity – in properly selected patients – to treat cancer with a much reduced side-effect profile that preserves quality of life, including less chance of urinary leakage and sexual issues, which are common results after a radical prostatectomy, the traditional treatment.

On Dec. 4, 2015, 61-year-old Graceville, Fla., resident Daniel Hazell was the first patient of Scionti’s to be treated with HIFU on American soil. While he did not have to travel to a foreign country for his HIFU procedure – he was prepared to do so prior to the FDA clearance.

“Dr. Scionti explains all available options, but HIFU sounded best to me because it targeted only the cancer cells and had a speedy recovery time,” Hazell said. “Scionti’s bedside manner also made me really comfortable; I knew I was in good hands. Most doctors don’t spend a lot of time with you, but he does.”

Hazell says that just hours after his procedure he was able to go out to dinner, and two days later, he is feeling good.

“The success of Mr. Hazell’s case is the result of many of years of hard work. His procedure went smoothly – it was typical of how my procedures go,” Scionti said. “A rapid return to normalcy is a major advantage with HIFU. Within a week, patients won’t even notice that they had a procedure done.”

Patients are not the only ones to directly benefit from Scionti’s experience. Scionti is directly involved in the training process for urologists interested in incorporating HIFU technology into their practices. He has proctored procedures of more than 80 urologists at Sonacare’s international centers of excellence and served as director of Clinical Education and Training for USHIFU and SonaCare Medical, the manufacturer of the Sonablate.

“With HIFU, you cannot shortcut training or experience, which is why Vituro Health guides partner physicians through the extensive training protocol that is required to master highly complex HIFU procedures,” Scionti said. “If you’re a patient and want the advantages of this non-invasive revolutionary technology, do your homework and find the best physician with the most HIFU experience that you can; good outcomes are obtained by skilled and highly experienced HIFU physicians.”

“Dr. Scionti honestly is the best in this field – he’s done more HIFU cases than anyone else in the country,” said Clete Walker, CEO of Vituro Health. “Vituro Health wanted to partner with the leading physician so we can educate our patients and physician partners because that’s the most important thing.”

“If people are willing to trust their prostate health to a new procedure, they want to trust it to someone who has the most experience with this revolutionary procedure. In my opinion, that is Dr. Scionti,” Walker said.

Scionti will perform ten more HIFU procedures in 2015 and has several already scheduled for early 2016.

For more information: www.viturohealth.com

 

Related Content

Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...